IndraLab

"In this study, we found that several lncRNAs, including FGD5-AS1, RAP2C-AS1, SUCLG2-AS1, USP46-AS1, AL391121.1, ENSG00000271020, AC112220.2, AC018647.2, AC015922.2, MID1IP1-AS1, AL731577.2 and AL450326.1 were co-expressed with VHL, and their expression were positively correlated with VHL expression."

"Lower expression of FGD5-AS1, RAP2C-AS1, SUCLG2-AS1, AL391121.1, AC112220.2, AC018647.2, AC015922.2 and AL450326.1 were associated with advanced tumor stage (Figure xref A); lower expression of RAP2C-AS1 was related to lymphatic invasion (Figure xref B); lower expression of RAP2C-AS1, USP46-AS1, AC112220.2 and AC015922.2 tended to promote tumor metastasis (Figure xref C); lower FGD5-AS1, RAP2C-AS1, SUCLG2-AS1, USP46-AS1, AL391121.1, AC112220.2, AC018647.2, AC015922.2 and AL450326.1 expression levels were correlated with higher pathological stage (Figure xref D); lower FGD5-AS1, RAP2C-AS1, SUCLG2-AS1, USP46-AS1, AL391121.1, AC112220.2, AC018647.2 and AC015922.2 expression levels were also correlated with higher histological grade (Figure xref E)."